31 CFR § 515.547 - Certain transactions related to medical research and Cuban-origin pharmaceuticals; research samples.

Date issued: Jun. 09 2022

TURBOFAC Commentary (86 words)

Notes:

1) GL unique to the CACR; the subject of non-substantive treatment at FAQ 115. Provision not subject to further publicly available guidance from OFAC.

2) Provision amended on 9-24-2020 to delete the reference to the general license for "professional meetings" (515.564(a)(2)). Provision amended again on 6-8-2022 to restore the language delated on 9-4-2020.

3) See Equillium, Inc., Q3 10-Q filing (2020), reporting an OFAC interpretation of this provision and the term "Cuban-origin pharmaceutical."